Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9402073rdf:typepubmed:Citationlld:pubmed
pubmed-article:9402073lifeskim:mentionsumls-concept:C0019693lld:lifeskim
pubmed-article:9402073lifeskim:mentionsumls-concept:C0086413lld:lifeskim
pubmed-article:9402073lifeskim:mentionsumls-concept:C0679646lld:lifeskim
pubmed-article:9402073lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:9402073lifeskim:mentionsumls-concept:C1317574lld:lifeskim
pubmed-article:9402073lifeskim:mentionsumls-concept:C0086931lld:lifeskim
pubmed-article:9402073lifeskim:mentionsumls-concept:C1456501lld:lifeskim
pubmed-article:9402073pubmed:issue4lld:pubmed
pubmed-article:9402073pubmed:dateCreated1997-12-22lld:pubmed
pubmed-article:9402073pubmed:abstractTextWe conducted a longitudinal study of participants in phase I and II HIV vaccine safety and immunogenicity trials to examine changes in sexual risk behavior that are associated with risk of HIV transmission. The participants were 48 HIV-negative men and women enrolled in one of two placebo-controlled HIV vaccine trials conducted at San Francisco General Hospital. There was a significant increase in insertive unprotected anal intercourse (UAI) from 9% at baseline (trial entry), to 13% at the month 6 assessment, to 20% at the month 12 assessment (p = .02). The primary predictor of either insertive or receptive UAI during the vaccine trials was having engaged in this behavior prior to entry (p = .001). Higher-risk behavior was also seen among participants who were younger and had multiple sexual partners (each, p = .06) and who indicated that one of their reasons for participation in the vaccine trial was hope of protection from HIV infection (p = .07). These findings indicate that despite instructions otherwise, participants with a history of high-risk behavior or who express hope of protection from HIV infection by enrolling in vaccine trials may be candidates for more intensive risk-behavior counseling prior to and during their participation.lld:pubmed
pubmed-article:9402073pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9402073pubmed:languageenglld:pubmed
pubmed-article:9402073pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9402073pubmed:citationSubsetIMlld:pubmed
pubmed-article:9402073pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9402073pubmed:statusMEDLINElld:pubmed
pubmed-article:9402073pubmed:monthDeclld:pubmed
pubmed-article:9402073pubmed:issn1077-9450lld:pubmed
pubmed-article:9402073pubmed:authorpubmed-author:KralV AVAlld:pubmed
pubmed-article:9402073pubmed:authorpubmed-author:ChesneyM AMAlld:pubmed
pubmed-article:9402073pubmed:authorpubmed-author:ChambersD BDBlld:pubmed
pubmed-article:9402073pubmed:issnTypePrintlld:pubmed
pubmed-article:9402073pubmed:day1lld:pubmed
pubmed-article:9402073pubmed:volume16lld:pubmed
pubmed-article:9402073pubmed:ownerNLMlld:pubmed
pubmed-article:9402073pubmed:authorsCompleteYlld:pubmed
pubmed-article:9402073pubmed:pagination266-71lld:pubmed
pubmed-article:9402073pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:9402073pubmed:meshHeadingpubmed-meshheading:9402073-...lld:pubmed
pubmed-article:9402073pubmed:meshHeadingpubmed-meshheading:9402073-...lld:pubmed
pubmed-article:9402073pubmed:meshHeadingpubmed-meshheading:9402073-...lld:pubmed
pubmed-article:9402073pubmed:meshHeadingpubmed-meshheading:9402073-...lld:pubmed
pubmed-article:9402073pubmed:meshHeadingpubmed-meshheading:9402073-...lld:pubmed
pubmed-article:9402073pubmed:meshHeadingpubmed-meshheading:9402073-...lld:pubmed
pubmed-article:9402073pubmed:meshHeadingpubmed-meshheading:9402073-...lld:pubmed
pubmed-article:9402073pubmed:meshHeadingpubmed-meshheading:9402073-...lld:pubmed
pubmed-article:9402073pubmed:meshHeadingpubmed-meshheading:9402073-...lld:pubmed
pubmed-article:9402073pubmed:meshHeadingpubmed-meshheading:9402073-...lld:pubmed
pubmed-article:9402073pubmed:meshHeadingpubmed-meshheading:9402073-...lld:pubmed
pubmed-article:9402073pubmed:meshHeadingpubmed-meshheading:9402073-...lld:pubmed
pubmed-article:9402073pubmed:meshHeadingpubmed-meshheading:9402073-...lld:pubmed
pubmed-article:9402073pubmed:meshHeadingpubmed-meshheading:9402073-...lld:pubmed
pubmed-article:9402073pubmed:meshHeadingpubmed-meshheading:9402073-...lld:pubmed
pubmed-article:9402073pubmed:meshHeadingpubmed-meshheading:9402073-...lld:pubmed
pubmed-article:9402073pubmed:meshHeadingpubmed-meshheading:9402073-...lld:pubmed
pubmed-article:9402073pubmed:meshHeadingpubmed-meshheading:9402073-...lld:pubmed
pubmed-article:9402073pubmed:year1997lld:pubmed
pubmed-article:9402073pubmed:articleTitleRisk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note.lld:pubmed
pubmed-article:9402073pubmed:affiliationCenter for AIDS Prevention Studies, Department of Medicine, University of California, San Francisco, 94105, USA. margaret_chesney@quickmail.ucsf.edulld:pubmed
pubmed-article:9402073pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9402073pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9402073lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9402073lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9402073lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9402073lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9402073lld:pubmed